Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 vs Taxotere in Advanced NSCLC
NCT05863325Phase 2Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of albumin-bound docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Overall Response Rate up to 3 years. Started Jun 2023; status: recruiting.
02
Drugs
albumin-bound docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05863325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05863325.